Clinical Trials
168 trialsNCT03223610 2026-06-05
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT04188405 2026-06-05
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04550442 2026-06-05
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04840602 2026-06-05
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05053659 2026-06-05
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05360160 2026-06-05
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05453903 2026-06-05
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05554393 2026-06-05
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05554406 2026-06-05
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05564390 2026-06-05
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05963074 2026-06-05
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06317649 2026-06-05
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06651229 2026-06-05
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06852222 2026-06-05
cAMeLot-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04161885 2026-06-04
VIALE-T
AbbVie
Phase 3 Terminated
NCT06943872 2026-06-04
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT05091424 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT06317662 2026-06-03
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07007312 2026-06-03
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
NCT07231952 2026-06-03
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07277231 2026-06-03
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
NCT07623187 2026-06-03
EVICTION 3
Ipsen
Phase 2/3 Not yet recruiting
NCT04623541 2026-06-02
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT05753501 2026-06-02
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Phase 1 Active not recruiting
NCT06672146 2026-06-02
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03319901 2026-06-01
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT04284787 2026-06-01
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04739813 2026-06-01
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05951959 2026-06-01
TrAVeRse
AstraZeneca
Phase 2 Active not recruiting
NCT06073821 2026-06-01
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT06372717 2026-06-01
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Apollo Therapeutics Ltd
Phase 1 Recruiting
NCT07604233 2026-06-01
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT03504644 2026-05-29
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Eastern Cooperative Oncology Group
Phase 1/2 Active not recruiting
NCT03701282 2026-05-29
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03737981 2026-05-29
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03984448 2026-05-29
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT06445907 2026-05-29
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06846671 2026-05-29
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
NCT07387471 2026-05-29
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
Phase 2 Recruiting
NCT05157971 2026-05-28
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05734495 2026-05-28
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07605949 2026-05-27
RAVEN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT04628026 2026-05-26
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
Phase 3 Recruiting
NCT06763341 2026-05-22
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT02115295 2026-05-20
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03613532 2026-05-20
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03629171 2026-05-20
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04774393 2026-05-20
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04802590 2026-05-20
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Active not recruiting
NCT03710772 2026-05-19
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting